Kerala HC: Persons With Down Syndrome Get Protection and Guardianship under National Trust Act, 1999 || J&K&L HC: Contractual Staff Cannot Claim Payment Beyond Contract Period Without Proving Work || J&K&L HC: Revisional Powers U/S 15 Must be Exercised in Reasonable Time, Not After 20-Year Delay || MP High Court: Revoking Building Permission Without Fraud Proof Violates Right to Property || Madras HC: Centre’s Consent For Remission is Needed only When Sentence under Central Act is Ongoing || Delhi HC: Private School Employees Entitled to Child Care Leave Equivalent to Government Employees || Supreme Court Has Released Draft Regulations on AI Use in the Judiciary and Invited Public Feedback || Supreme Court: MMDR Act Royalty Hikes Prevail over Contractual Terms || Delhi HC: Daughter-In-Law Has No Independent Right in Mother-In-Law’s Self-Acquired House || SC: Prolonged Separation Can Constitute Cruelty and Desertion

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK MERCK PATENT DIABETES

Share :